Shaw Patterns of Resistance in ALK Positive NSCLC

(6:2)

Case Study: Progression on ALK Inhibitors in NSCLC

(6:4)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)

Updates and unmet needs in ALK-mutated lung cancer

(1:25)

ALK Inhibitor Sequencing in NSCLC

(6:27)

Choosing the best ALK inhibitor for lung cancer

(1:24)

What is treatment like for ALK-positive lung cancer?

(2:12)

2023 Best of Lung: Targeted Therapies in Lung Cancer

(30:32)

Second-Line Treatment for ALK-Positive NSCLC

(8:24)

Case Presentation: ALK-Rearranged Metastatic NSCLC

(2:49)

What is an ALK rearrangement in lung cancer?

(1:33)

DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib

(13:28)

Emerging ALK/ROS1 TKIs for NSCLC

(4:49)

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

(59)

Highlights on adjuvant alectinib in early ALK positive NSCLC: The ALINA study

(2:51)

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

(1:57)

NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC

(56)

What targeted therapies are used for people with the ALK mutation?

(1:5)

ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

(9:49)

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

(42:31)